Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05199389 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy

Study acronym: NeuroLight
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Nov 10, 2023 to Nov 15, 2023v6
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Dec 22, 2023 to Nov 10, 2023
    • Study completion date: Dec 22, 2028 to Nov 10, 2028
    • Site details revised
    v5
  3. Enrollment target: 30 to 60v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 24, 2022 to Jan 31, 2022
    • Site details revised
    v3
  5. Secondary endpoints: details revised at 3 of 6 entries
    • Study title shortened, about 1 word
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the management of chemotherapy-induced peripheral neuropathy (CIPN). Therefore, the hypothesis is that PBM can reduce the severity of CIPN in cancer patients, increasing the patient's quality of life.
Trial Details
NCT Number NCT05199389
Lead Sponsor Jessa Hospital
Conditions
(from sponsor)		 Chemotherapy-induced Peripheral Neuropathy
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov